- Nano cap Anthera Pharmaceuticals (ANTH +8.6%) adds to yesterday's breakout on triple normal volume. Shares have jumped ~30% since then after the company announced the completion of enrollment in a Phase 3 clinical trial, RESULT, assessing Sollpura for the treatment of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis.
- The primary endpoint is non-inferiority to porcine pancreatic enzyme replacement therapy (PERT) [J&J's PANCREAZE (pancrelipase)] at week 8 as measured by coefficient of fat absorption (CFA). Topline results should be available in Q1 2018.
- An earlier Phase 3 study, SOLUTION, failed to achieve the same endpoint.
- Sollpura is a non-porcine PERT containing a proprietary engineered cross-linked formulation of crystalline lipase, crystalline protease and amorphous amylase. The company says its solubility and stability offers a more patient-friendly alternative for those who cannot swallow multiple pills or require gastric tubes in order to maintain their nutritional health.
- Previously: Anthera drops 66% as Sollpura misses study target (Dec. 27, 2016)
- Now read: Eli Lilly Q3 2017: Mixed Signals
Original article